|Bid||35.74 x 1000|
|Ask||37.81 x 1000|
|Day's range||35.95 - 36.91|
|52-week range||22.65 - 48.95|
|Beta (5Y monthly)||1.52|
|PE ratio (TTM)||N/A|
|Earnings date||06 Aug 2020 - 10 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||58.22|
TOKYO and SAN FRANCISCO, May 21, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique.
Ladies and gentlemen, thank you for standing by, and welcome to the FibroGen First Quarter 2020 Financial Results. Thank you for joining us on today's call to discuss FibroGen's results for the first quarter of 2020. Today's call will be led by Enrique Conterno, our Chief Executive Officer.
SAN FRANCISCO, May 08, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May.
FibroGen (FGEN) delivered earnings and revenue surprises of -196.67% and -64.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Roxadustat U.S. NDA review and E.U. MAA filing on track - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, May 07, 2020 -- FibroGen,.
SAN FRANCISCO, April 24, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020. FibroGen will also conduct a.
FibroGen, Inc. (FGEN) today announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) to be invalid. This decision does not affect the validity of these patents across the rest of Europe. While FibroGen is disappointed with the court’s decision, this UK ruling does not affect development or commercialization timelines for roxadustat, FibroGen’s HIF-PHI for treatment of anemia in chronic kidney disease, including in the UK or elsewhere in Europe.
FibroGen (FGEN) delivered earnings and revenue surprises of -80.65% and -74.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO (AP) _ FibroGen Inc. (FGEN) on Monday reported a fourth-quarter loss of $98.1 million, after reporting a profit in the same period a year earlier. The results missed Wall Street expectations. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced.
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, Feb. 18, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2019 financial results after market close on Monday, March 2, 2020..
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
FibroGen, Inc. (FGEN) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review of its New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) patients. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of December 20, 2020. “The FDA’s acceptance of the roxadustat new drug application is a critical step towards providing a new treatment option in the United States for chronic kidney disease patients suffering from anemia, a serious and often life-threatening disease,” said Enrique Conterno, Chief Executive Officer, FibroGen.
SAN FRANCISCO, Feb. 11, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020. Enrique.
Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. The investigation concerns whether FibroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
FibroGen, Inc. (FGEN) announced that its Board of Directors unanimously appointed Enrique Conterno as the company’s Chief Executive Officer and a member of the Board of Directors, effective today. Conterno previously worked as a senior vice president for Eli Lilly and Company, serving as President, Lilly USA, President, Lilly Diabetes, and a member of Lilly’s corporate executive committee.
FibroGen, Inc. (FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) CKD patients. Roxadustat is the first orally administered small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor submitted for FDA regulatory approval for the treatment of anemia of CKD.
FibroGen, Inc. (FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA). Roxadustat is included on the NRDL for the treatment of anemia in chronic kidney disease (CKD), covering patients who are non-dialysis-dependent (NDD) as well as those who are dialysis-dependent (DD). “Inclusion on the NRDL is a significant milestone and inflection point for the growth trajectory for roxadustat, as reimbursement provides affordability and access for patients on a national basis,” said Jim Schoeneck, Interim CEO, FibroGen.
SAN FRANCISCO, Nov. 13, 2019 -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors who have suffered significant losses to submit their loss now to learn if they.